Structure Encountered

Nucs AI

AI-powered PSMA PET/CT diagnostics for oncology treatment prediction and response

Nucs AI will adapt its response-prediction platform to AstraZeneca's PSMA radioconjugate in prostate cancer.

SIGNAL·Research collaboration, AI response prediction·AstraZeneca·SCORE 64·02 JUN 2026 · 11:54 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

STRUCT. / NUCS AI

/ New York, NY, USA

CAPT. / 02.06.26 11:54:29Z

SIGNAL / 64 / 100

Image relayed by The Biotech Voyager during pass over structure Nucs AI. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Nucs AI

Coordinates

New York, NY, USA

Stage

Preclinical

Type

Diagnostics

Modalities

AI/ML · biomarker · radiopharmaceutical · software

Therapeutic area

Oncology

002Signature Detected

EVENT DETECTED

Event type

Research collaboration, AI response prediction

Magnitude

AstraZeneca

Lead

AstraZeneca

003Architecture

PLATFORM PROFILE

Target class

PSMA (prostate-specific membrane antigen), the surface target for PSMA PET imaging and Lutetium-177 radioligand therapy in metastatic castration-resistant prostate cancer.

Differentiator

Most radioligand selection stops at eligibility: who has enough PSMA to qualify. Nucs AI models who will respond and how each tumor tracks across treatment, a prediction layer a pharma can bolt onto a crowded PSMA field.

Lead asset

Response-prediction platform (DeepPSMA, SelectPSMA, TrackPSMA)

Pipeline depth

1 platform, 3 modules; AstraZeneca + Johns Hopkins collaborations

004Voyager Assessment

MACHINE-GENERATED

Radioligand therapy has a selection problem. PSMA PET tells you who is eligible, not who will respond, and as the PSMA field crowds with Lutetium and now actinium players, that gap is where the money is. Nucs AI built its whole platform on predicting response, trained on Lutetium therapy, and AstraZeneca is now adapting it to its own undisclosed PSMA radioconjugate in metastatic prostate cancer. No terms disclosed, which tells you it is early. But a 2024 startup getting a big pharma to validate its prediction layer is the signal. Watch whether this turns into a companion-diagnostic play.

005Adjacent Structures

FRONTIER MAP

Novartis· Pluvicto incumbentLantheus· PSMA PET imagingTelix Pharmaceuticals· PSMA theranosticsPOINT Biopharma· PSMA radioligand (Lilly)Aktis Oncology· radioconjugate peer

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.